Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children
| Autor: | Fran Newman, Sharon L. Nugent, Robert B. Belshe, Edwin L. Anderson, M H Wilson, S L Hall, E L Tierney, M Steinhoff, M L Clements, R A Karron |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Microbiology (medical)
Paramyxoviridae Molecular Sequence Data Antibodies Viral Vaccines Attenuated Virus Double-Blind Method medicine Humans Viral shedding Child Paramyxoviridae Infections rhinorrhea Base Sequence biology business.industry Immunogenicity Viral Vaccine Infant Viral Vaccines biology.organism_classification Adaptation Physiological Virology Parainfluenza Virus 3 Human Cold Temperature El Niño Child Preschool DNA Viral Immunology biology.protein medicine.symptom Antibody business Research Article |
| Zdroj: | Journal of Clinical Microbiology. 30:2064-2070 |
| ISSN: | 1098-660X 0095-1137 |
| Popis: | Cold passage 18 (CP18) parainfluenza virus type 3 (PIV-3) vaccine was evaluated in a double-blind, randomized, placebo-controlled study of 95 infants and young children. None of 19 seropositive older children 41 to 124 months old became infected when 10(6) 50% tissue culture infective doses (TCID50) of vaccine virus was administered intranasally. Two of nine and seven of twenty-four young seropositive children given 10(5) or 10(6) TCID50 of CP18 PIV-3, respectively, became infected. Each of four seronegative young children became infected, as indicated by virus shedding and antibody response, when given 10(6) TCID50 of CP18 PIV-3 intranasally. Illness was not observed in seropositive children. Two of the four seronegative children developed a mild illness characterized by rhinorrhea and wheezing on auscultation; none had fever. In one case, vaccine virus spread from a vaccine to a sibling control but did not cause illness. The vaccine is attenuated relative to wild-type PIV-3, but additional attenuation will be required to achieve a satisfactory PIV-3 vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|